A report from the EMAs PRAC, published on 12 April 2024, said: After reviewing the available evidence from non-clinical studies, clinical trials, post-marketing surveillance data and the available studies the PRAC considers that no update to the product information is warranted. The PRAC statement said that market authorisation holders would continue to monitor events, including new studies, as part of their pharmacovigilance activities
And regardless, patient should get a baseline comprehensive eye exam before or shortly after starting a GLP-1 and repeat that examination at least annually, because thats frankly just good diabetes care
By replenishing GSH reserves in the liver, more toxic paracetamol metabolites are neutralised
Glucagon-like peptide-1 receptor agonists (GLP-1a) act on numerous pathways that intersect glycemic, weight, and blood pressure (BP) control
Plain and simple, McGowan said